You are here

Article Text

Article menu
Download PDFPDF
Short report
Assessment of ALK gene rearrangement in lung cancer using a new rapid automated SureFISH (Dako Omnis) assay
  1. Maiko Takeda1,
  2. Takahiko Kasai1,
  3. Shigeki Shimizu2,
  4. Masanori Kitaichi3,
  5. Kensuke Kojima4,
  6. Akihiro Nagoya4,
  7. Akio Hayashi4,
  8. Tomoki Utsumi4,
  9. Hyung-Eun Yoon4,
  10. Akihide Matsumura4,
  11. Shinji Atagi5
  1. 1Department of Laboratory Medicine and Pathology, National Hospital Organization Kinki-chuo Chest Medical Center, Osaka, Japan
  2. 2Department of Pathology, Kinki University of Medicine, Osaka-Sayama, Japan
  3. 3Department of Laboratory Medicine and Pathology, National Hospital Organization Minami Wakayama Medical Center, Wakayama, Japan
  4. 4Department of Surgery, National Hospital Organization Kinki-chuo Chest Medical Center, Osaka, Japan
  5. 5Department of Thoracic Oncology, National Hospital Organization Kinki-chuo Chest Medical Center, Osaka, Japan
  1. Correspondence to Dr Maiko Takeda, Department of Laboratory Medicine and Pathology, National Hospital Organization Kinki-chuo Chest Medical Center, 1180 Nagasone-cho, Kita-ku, Sakai City, Osaka 591-8555, Japan; maikot{at}naramed-u.ac.jp

Abstract

The ALK fluorescence in situ hybridisation (FISH) method is the examination essential for pathological diagnosis and choice of molecular-targeted therapy in ALK-rearranged lung cancer. Here, for detection of ALK gene rearrangement in patients with lung cancer, we evaluated the rapid FISH technology (ALK SureFISH), a newly developed assay for the automated staining platform Dako Omnis, using 21 formalin-fixed paraffin-embedded (FFPE) samples. All cases could be evaluated with the SureFISH method. SureFISH provided excellent quality signals without any background staining. The SureFISH assay was able to offer a rapid turnaround time (approximately 3.5 hours) and was 100% concordant with prior Vysis FISH results in our laboratory.

  • LUNG CANCER
  • FISH
  • MOLECULAR PATHOLOGY

https://doi.org/10.1136/jclinpath-2016-204311

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Handling editor Runjan Chetty

    • Contributors MT contributed to corresponding author, study design, data collection, review of pathology samples, data analysis and manuscript write-up. TK contributed to study design, data analysis and manuscript editing. SS and MK contributed to data collection and review of pathology samples. KK, AN, AH, TU, H-EY, AM and SA contributed to data collection.

    • Competing interests None declared.

    • Patient consent Obtained.

    • Ethics approval Institutional Review Board.

    • Provenance and peer review Not commissioned; externally peer reviewed.